Form 8-K · Current report
DaVita 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000927066
- Accession no.
- 0000927066-26-000105
Summary
DaVita Inc. reported second-quarter 2026 consolidated revenues of $3.554 billion, operating income of $579 million, and diluted earnings per share of $4.02, and provided 2026 guidance for adjusted operating income of $2.15–$2.25 billion, adjusted diluted EPS of $14.10–$15.20, and free cash flow of $1.0–$1.25 billion. CEO Javier Rodriguez said the quarter was positive for patient outcomes and financial results and that DaVita remains focused on innovations in kidney dialysis.
Key points
- DaVita repurchased 2.2 million shares for $348 million at an average price of $154.95 per share during the second quarter, and repurchased 0.2 million shares for $37 million at an average price of $199.55 per share after June 30 through August 4, 2026.
- DaVita incurred a $500 million incremental Term Loan B-2 tranche in June 2026 and used part of the proceeds to repay a portion of its revolving line of credit.
- As of June 30, 2026, DaVita served approximately 298,500 patients at 3,266 outpatient dialysis centers, including 2,671 centers in the United States and 595 centers in 14 other countries.
- U.S. dialysis treatments totaled 7,226,600 in the second quarter of 2026, or an average of 92,649 treatments per day, up 1.09% from the first quarter of 2026, with normalized non-acquired treatment growth of 0.3% year over year.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 4, 2026, DaVita Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information contained in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.